

Published in final edited form as:

*Bioanalysis*. 2013 June ; 5(12): . doi:10.4155/bio.13.91.

## Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method

Liusheng Huang<sup>\*</sup>, Alexander Olson, David Gingrich, and Francesca T Aweeka

Drug Research Unit, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94110, USA

### Abstract

**Background**—Numerous methods have been reported for the determination of artemether (ARM) and its metabolite dihydroartemisinin (DHA) in plasma. However, stability issues in patient plasma have not received enough attention.

**Results**—An LC–MS/MS method for simultaneous determination of ARM and DHA in human plasma (K<sub>3</sub>EDTA) turned out to be problematic: ARM and DHA were degraded partially or completely in some patient plasma samples as indicated by the stable isotope-labeled internal standards. We postulated iron II (Fe<sup>2+</sup>) in hemoglobin or its derived products from malaria patients causes degradation of the drugs, and found that hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) protected the drugs from degradation. Acidifying plasma increased recovery of ARM significantly. Using only 50 µl of plasma sample, the method has a LLOQ at 0.5 ng/ml for both ARM and DHA.

**Conclusion**—H<sub>2</sub>O<sub>2</sub> is a stabilizing agent for artemisinin derivatives. The modified method is reliable and sensitive.

Numerous methods have been reported for the determination of artemether (ARM) and its metabolite dihydroartemisinin (DHA) in plasma from malaria patients [1–6]. Few of the reported methods have addressed stability issues when quantitating the drugs within plasma generated from patients infected with the malaria parasite. For the first time, Lindegardh *et al.* reported degradation of artemisinin derivatives during sample preparation, as indicated by the stable isotope-labeled internal standard (IS), and the issue was solved by using SPE and dissolving IS in 50% plasma [7]. At around the same time, Keiser *et al.* reported the stability issue of artesunate and DHA in hemolyzed rat plasma, and they solved the problem by using sodium nitrite to pre-treat the samples [8]. Hodel *et al.* confirmed the findings using direct injection of supernatant from protein precipitation, but they reported that evaporation and reconstitution following protein precipitation prevents ARM, DHA and artesunate from degrading [9]. Wiesner *et al.* utilized a liquid–liquid extraction method that

© 2013 Future Science Ltd

<sup>\*</sup>Author for correspondence: Tel.: +1 415 502 2594, huangl@sfghsom.ucsf.edu.

#### Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: [www.future-science.com/doi/full/10.4155/BIO.13.91](http://www.future-science.com/doi/full/10.4155/BIO.13.91)

#### Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

#### Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

seems to withstand the degradation pitfall [6]. Our method utilized SPE, similar to that used in Lindegardh's group. Degradation of ARM and DHA was also found in some patient plasma samples. Furthermore, we identified a new stabilization agent, hydrogen peroxide ( $\text{H}_2\text{O}_2$ ), and the LLOQ of the method was approximately threefold lower than that reported by Lindegardh's group, using the same plasma volume.

## Experimental

### Chemicals & reagents

ARM and DHA were purchased from AK Scientific, Inc., (CA, USA). ARM- $^{13}\text{CD}_3$  (isotopic purity >99%) was obtained from Novartis (Basel, Switzerland) as a gift and DHA- $\text{d}_3$  (isotopic purity >99%) was purchased from Toronto Research Chemicals, Inc. (Toronto, Canada).  $\text{K}_3\text{-EDTA}$  was used as the anticoagulant for human plasma samples. All solvents and common reagents were purchased from Thermo-Fisher Scientific, Inc (MA, USA).

The structures of ARM, ARM- $^{13}\text{CD}_3$ , DHA and DHA- $\text{d}_3$  are shown in Figure 1. Stable isotope-labeled analytes are considered to be the best choice of IS for quantification methods using a mass spectrometer as the detector, because they are generally co-eluted and ionized similarly with the analytes. Signal variation for analytes (due to sample preparation, instrument and matrix effect) could be best compensated by this kind of IS. In general,  $^{13}\text{C}$  labeling is better than deuterium labeling in terms of co-elutability and ionization similarity with the corresponding analyte. In this assay we chose deuterated IS, solely based on availability. One disadvantage is that the deuterated ISs are not completely overlapped with the corresponding peaks of ARM and DHA (~0.2 min separation).

### Sample preparation

Plasma samples (50  $\mu\text{l}$ ) were mixed with 50  $\mu\text{l}$  IS solution (5 ng/ml ARM- $^{13}\text{CD}_3$  and DHA- $\text{d}_3$  in 5% acetonitrile with 1% formic acid and 1%  $\text{H}_2\text{O}_2$ ) in wells of Oasis HLB  $\mu\text{Elution}$  plate (2 mg sorbent per well, 30  $\mu\text{m}$  particle size, Waters, Inc., MA, USA). The mixtures were drained slowly under mild vacuum (2–5 inHg). The wells were washed with water 200  $\mu\text{l}$  once and 5% acetonitrile 200  $\mu\text{l}$  once subsequently under vacuum (5–8 inHg). The receiver plate was emptied at each step. The wells were eluted with acetonitrile-methyl acetate (9:1) 25  $\mu\text{l}$  twice under mild vacuum (2–5 inHg). The combined eluent was injected (10  $\mu\text{l}$ ) for LC-MS/MS analysis.

### LC-MS/MS analysis

AB Sciex API5000 (MA, USA) coupled with Shimadzu Prominence UFLC 20AD<sup>XR</sup> (Kyoto, Japan) pumps and a SIL-20AC<sup>XR</sup> AutoSampler (Shimadzu) was used. A LC-MS gas generator (Source 5000<sup>TM</sup>, Parker Balston, MA, USA) was connected to the LC-MS/MS system. Separation was achieved on Acquity HSS  $\text{C}_{18}$  column (100  $\times$  2.1 mm, 1.8  $\mu\text{m}$ , Waters, Inc) eluted in a gradient mode with 10 mM ammonium formate at pH = 4.0 and acetonitrile (0.1% formic acid) at a flow rate of 0.3 ml/min. Acetonitrile % (time, min): 50 (0 min)  $\rightarrow$  50 (0.5 min)  $\rightarrow$  100 (6.5 min)  $\rightarrow$  100 (7.5 min)  $\rightarrow$  50 (7.6 min)  $\rightarrow$  50 (9.0 min). The mass spectrometer was set at ESI<sup>+</sup> and SRM mode. The optimized MS parameters are listed in Tables 1 & 2.

## Results & discussion

Our laboratory previously developed a method to quantify ARM and DHA in human plasma based on a API2000 MS/MS [5]. In that method, 0.5 ml plasma sample was used and the LLOQ was 2 ng/ml. The method was applied to clinical studies on healthy subjects. We realized that a LLOQ below 1 ng/ml is better, in order to collect sufficient data for


estimation of the elimination half-life. To support pediatric PK studies, a more sensitive method is needed. Initially we intended to transfer the method to the API5000 system with the following modifications:

- Plasma sample volume reduced to 50  $\mu$ l;
- **Micro-elution HLB plate** (2 mg sorbent per well), suitable for small sample volume, used to replace HLB cartridge (10 mg sorbent) for SPE;
- Analytical column Acquity UPLC<sup>®</sup> HSS C<sub>18</sub> (2.1  $\times$  100 mm, 1.8  $\mu$ m) used instead of Symmetry C<sub>18</sub> (4.6  $\times$  150 mm, 5  $\mu$ m);
- IS utilized their corresponding stable isotope-labeled drugs instead of artemisinin.

The LLOQ of the new method was 0.5 ng/ml for both ARM and DHA (S/N is 20 and 8, respectively), reduced by fourfold compared with our previous method, and plasma sample volume was reduced by tenfold. The representative chromatograms of blank plasma and LLOQ are shown in Figure 2. The method was validated (see Supplementary Data) according to the AIDS Clinical Trials Group network guidelines [10], which was based on US FDA guidelines.

However, when the method was applied to clinical samples from malaria patients, the IS signal diminished or even disappeared in some hemolyzed plasma samples as well as in some samples without obvious **hemolysis**; a phenomenon also observed by Lindegardh *et al.* and Keiser *et al.* Furthermore, we also observed that IS was not degraded in some hemolyzed samples (Supplementary Table 1). These results suggest it is not hemolysis itself but the specific hemolytic product that causes degradation of ARM and DHA. We believe that it is the Fe<sup>2+</sup>-containing hemolytic products that cause the degradation of artemisinin and its derivatives. Interestingly, these analytical issues have not been acknowledged by other groups. Wiesner *et al.* reported a liquid–liquid extraction method with ethyl acetate [6]. No degradation of ARM and DHA was observed when tested with 1–2% hemolyzed plasma samples, and the IS levels were consistent when the method was applied to clinical samples. Hodel *et al.* noticed approximately 20% degradation of artemisinin using 0.2% hemolyzed plasma samples and over 50% degradation in samples from some malaria patients, but evaporation and reconstitution steps reportedly helped to stabilize the drugs [7]. In reality, clinical samples could be contaminated by hemolytic products at various levels, and percentage degradation of artemisinins also depends on the concentration of the drugs. Since digestion of hemoglobin by malaria parasites releases Fe<sup>2+</sup>-containing products, in plasma samples from malaria patients, the hemolytic products that contain Fe<sup>2+</sup> might also be varied in the context of different disease stages. In our previous method based on API2000, the degradation issue indicated by the IS artemisinin was not common; we only noticed a decrease of the IS signal in rare cases (ten out of 250 samples from healthy subjects with API2000 vs 61 out of 95 samples from patients with API5000) and the decrease of signal was typically no more than 50%. The most likely reason may be that this method has only been used for samples from healthy subjects, and the impact of the malaria parasite and heme generation through the pathologic process should not be present. It is also possible that the difference may be attributed to the instrument system used. API 2000 is much less sensitive, and a higher concentration of IS (100 ng/ml) was used in the assay. The degradation of ARM and DHA we have observed using our current API5000 method when analyzing these compounds in plasma from malaria-infected patients has confirmed the findings reported by Lindegardh's group.

Based on the hypothesis that degradation of ARM and DHA during sample analysis is caused by  $\text{Fe}^{2+}$ -containing products, we selected  $\text{H}_2\text{O}_2$  to remove  $\text{Fe}^{2+}$ . In acidic conditions,  $\text{H}_2\text{O}_2$  converted  $\text{Fe}^{2+}$  to  $\text{Fe}^{3+}$  according to the following reaction:



The IS (ARM- $^{13}\text{CD}_3$  and DHA- $\text{d}_3$ ) was dissolved in 5% acetonitrile, 1% formic acid and 1%  $\text{H}_2\text{O}_2$  (1:30 dilution from 30%  $\text{H}_2\text{O}_2$ ). A subset of patient samples was reanalyzed with this new IS solution. The signals for the IS were now consistent and deviation from the mean IS signal is less than 25% (square markers in Figure 3), in contrast with the results with initial solution (diamonds in Figure 3). The signals for ARM and DHA in those problematic samples were also higher and could be quantified (Supplementary Table 1). The same samples were also analyzed with the IS dissolved in 50% plasma (plasma diluted with equal volume of water), a method used by Lindegardh's group. Similar results were obtained (triangles in Figure 3); however, the IS signals were lower than that in our method, suggesting that partial degradation of artemisinin derivatives still occurred even with IS dissolved in 50% plasma (Figure 3). Nevertheless, this should not affect quantification because stable isotope-labeled drugs used as the IS would be degraded similarly to the drugs. The concentrations determined with the latter two IS solutions agree with each other with less than 20% difference for ARM in all 15 samples and less than 20% difference for DHA in 13 of 15 samples (Supplementary Table 1). Our method provided a better protection for the analysis of artemisinin derivatives in hemolyzed samples and samples from malaria patients. Interestingly, Keiser *et al.* used sodium nitrite to pre-treat the plasma samples from rat and achieved the same protection effect [8].

Of note, the new IS solution is not stable. Over time, a residual DHA peak was formed from DHA- $\text{d}_3$ . The conversion was less than 20% of LLOQ in 6 h but more than 20% after overnight standing on a bench (29.7% after 22 h at 20°C). ARM- $^{13}\text{CD}_3$  was not converted to ARM and no significant degradation observed when standing at room temperature overnight. The IS solution was stable for at least 1 month when stored at  $-70^\circ\text{C}$ . Therefore, the IS solution was stored at  $-70^\circ\text{C}$  in small aliquots (1–2 ml) and used within 1 day if thawed.

Our second finding is that acidification of plasma increased the recovery of ARM significantly. Without acidification of the plasma samples, the recovery of ARM was lower than DHA (52.2–62.7% vs 83.1–98.1%; Table 3). This difference may be attributed to higher plasma protein binding of ARM (95–98%) compared with DHA (47–93%) [11,12]. Acidification of plasma increased the recovery of ARM, probably due to disruption of drug–protein interactions. However, this also exposed the drugs to  $\text{Fe}^{2+}$  in plasma of certain patients, resulting in drug and stable isotope-labeled IS degradation. By adding  $\text{H}_2\text{O}_2$ ,  $\text{Fe}^{2+}$  was oxidized to  $\text{Fe}^{3+}$  and, thus, shielded the peroxide bridge of the artemisinin derivatives from  $\text{Fe}^{2+}$ .

Compared with the assay reported by Lindegardh's group, our assay has a lower LLOQ (0.5 ng/ml vs 1.43 ng/ml). This is mostly attributed to the smaller elution volume (50  $\mu\text{l}$  vs 100  $\mu\text{l}$  + 50  $\mu\text{l}$ ). As the S/N ratio for ARM was 20 at 0.5 ng/ml, its LLOQ could be lower. Higher sensitivity for ARM is attributed to acidification of plasma samples, leading to higher recovery. The sensitivity could also be improved if a better UPLC system was utilized (maximum system pressure 15,000 psi), enabling higher flow rate (0.6–0.8 ml/min).

In summary, ARM, DHA and their corresponding stable isotope-labeled IS – ARM- $^{13}\text{CD}_3$  and DHA- $\text{d}_3$  – were found to be degraded in some plasma samples from malaria patients

during sample analysis, and we found that H<sub>2</sub>O<sub>2</sub> protected ARM, DHA, ARM-<sup>13</sup>CD<sub>3</sub> and DHA-d<sub>3</sub> from degradation. Acidification of plasma during sample preparation increased recovery of ARM significantly. The new H<sub>2</sub>O<sub>2</sub> stabilization method, combined with a modified sample preparation method, enables us to develop a sensitive assay for ARM and DHA quantification, with a small sample volume (50 µl) and an LLOQ at 0.5 ng/ml.

## Future perspective

It is important to stabilize artemisinin derivatives in clinical studies [13]. Our results demonstrated that ARM and DHA are degraded in certain patient samples and hemolyzed samples during analysis. What exactly causes the degradation? Is there degradation of artemisinins during blood sample collection and storage? How can the blood samples be stabilized? Further studies are needed to answer these questions. H<sub>2</sub>O<sub>2</sub> is a promising stabilization agent for artemisinin derivatives. Although only ARM and DHA were tested in this work, it may be applied to other artemisinin derivatives. In this report only plasma samples were tested. Future study can be extended to blood samples.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was supported by NIH (R01 HD068174).

## Key Terms

<b>Micro-elution HLB plate</b>	Kind of SPE plate designed for small sample volume and small elution volume.
<b>Hemolysis</b>	Breakdown of red blood cells and release of hemoglobin into plasma.

## References

Papers of special note have been highlighted as:

- of interest
  - of considerable interest
1. Peys E, Vandekerckhove J, Van Hemel J, Sas B. Simultaneous determination of β-artemether and its metabolite dihydroartemisinin in human plasma and urine by a high-performance liquid chromatography-mass spectrometry assay using electrospray ionisation. *Chromatographia*. 2005; 61:637–641.
  2. Shi B, YU Y, Li Z, et al. Quantitative analysis of artemether and its metabolite dihydroartemisinin in human plasma by LC with tandem mass spectrometry. *Chromatographia*. 2006; 64:523–530.
  3. Souppart C, Gauducheau N, Sandrenan N, Richard F. Development and validation of a high-performance liquid chromatography–mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2002; 774:195–203.
  4. Hanpithakpong W, Kamanikom B, Singhasivanon P, White NJ, Day NPJ, Lindegardh N. A liquid chromatographic–tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma. *Bioanalysis*. 2009; 1:37–46. [PubMed: 21083186]

5. Huang L, Jayewardene AL, Li X, Marzan F, Lizak PS, Aweeka FT. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for determination of artemether and its active metabolite dihydroartemisinin in human plasma. *J. Pharm. Biomed. Anal.* 2009; 50:959–965. [PubMed: 19646837]
6. Wiesner L, Govender K, Meredith SA, Norman J, Smith PJ. A liquid-liquid LC/MS/MS assay for the determination of artemether and DHA in malaria patient samples. *J. Pharm. Biomed. Anal.* 2011; 55:373–378. [PubMed: 21353430] ■ Reports no degradation of artemether and dihydroartemisinin.
7. Lindegardh N, Hanpithakpong W, Kamanikom B, et al. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2008; 876:54–60. ■ Reports degradation of artemisinin derivatives in plasma from some malaria patients.
8. Keiser J, Gruyer MS, Perrottet N, Zanolari B, Mercier T, Decosterd LA. Pharmacokinetics parameters of artesunate and dihydroartemisinin in rats infected or not by *Fasciola hepatica*. *J. Antimicrob. Chemother.* 2009; 63:543–549. [PubMed: 19168863] ■ Reports some protection of artemether by sodium nitrite.
9. Hodel EM, Zanolari B, Mercier T, et al. A single LC tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2009; 877:867–886. ■ Reports controversial results that protein precipitation can withstand degradation if evaporation and reconstitution are applied.
10. AIDS Clinical Trials Group network guidelines for method development and validation based on (and including) FDA guidelines dated by 2001. Version. 2005; 2 ■ A revision was made in 2012 and posted in the Clinical Pharmacology Quality Assurance and Quality Control Program (available at: [www.fstrf.org](http://www.fstrf.org)).
11. Colussi D, Parisot C, Legay F, Lefèvre G. Binding of artemether and lumefantrine to plasma proteins and Erythrocytes. *Eur. J. Pharm. Sci.* 1999; 9:9–16. [PubMed: 10493991]
12. Batty KT, Ilett KF, Davis TM. Protein binding and  $\alpha$ : $\beta$  anomer ratio of dihydroartemisinin *in vivo*. *Br. J. Clin. Pharmacol.* 2004; 57:529–533. [PubMed: 15025754]
13. Blessborn D, Skölld K, Zeeberg D, Kaewkhao K, Sköld O Ahnoff M. Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds. *Bioanalysis.* 2013; 5(1):31–39. [PubMed: 23256470]


### Executive summary

#### Method development

- Sample preparation utilized a micro-elution SPE HLB plate, suitable for small sample volume.
- Acidification of plasma prior to extraction increased sensitivity of artemether (ARM) significantly.


#### Stability issues in application

- Degradation of ARM and dihydroartemisinin was found in some plasma samples from malaria patients, including both hemolyzed and nonhemolyzed samples.
- Hydrogen peroxide is an efficient stabilization agent to protect ARM and dihydroartemisinin from degradation.




**Figure 1. Artemether, dihydroartemisinin and their corresponding internal standards**





**Figure 2.** Chromatograms of blank plasma (light line) and samples at LLOQ level (dark line)  
DHA: Dihydroartemisinin.



**Figure 3. Comparison of signal intensity of internal standard for patient samples when added in three different solutions**

**(A)** Artemether-<sup>13</sup>CD<sub>3</sub> and **(B)** dihydroartemisinin-d<sub>3</sub>.

IS: Internal standard.

**Table 1**

MS source parameters for artemether and dihydroartemisinin.

Source temperature (°C)	Ion spray voltage (V)	Curtain gas (psi)	Nebulizer gas (psi)	Auxiliary gas (psi)	Auxiliary (turbo) gas (psi)	Collision-activated dissociation (psi)
300	5500	30	90	20	20	7

**Table 2**

MS compound parameters for artemether and dihydroartemisinin.

Compound parameters	Declustering potential (v)	Entrance potential (v)	Collision energy (v)	Collision cell exit potential (v)
Artemether, 316/267 <sup>†</sup>	46	10	12	22
Dihydroartemisinin, 302/163 <sup>†</sup>	31	10	21	18

<sup>†</sup>Precursor/product ion pair.

The internal standards artemether-<sup>13</sup>CD<sub>3</sub> (320/267<sup>†</sup>) and dihydroartemisinin-d<sub>3</sub> (305/166<sup>†</sup>) have the same parameters as their corresponding analytes.

**Table 3**

Recovery of artemether and dihydroartemisinin.

Analyte	Concentration (ng/ml)	Recovery (%)	
		With 1% formic acid	Without acidification
ARM	1.5	116	52.2
	170	122	62.7
DHA	1.5	100	83.1
	170	103	98.1

Recovery with 1% formic acid was obtained by mixing low and high QC samples in triplicate with internal standard solution containing 1% formic acid and then processing with HLB micro-elution plate. Recovery without acidification was obtained by mixing low and high QC samples in triplicate with internal standard solution that was not acidified.

ARM: Artemether; DHA: Dihydroartemisinin.